肥胖
医学
重症监护医学
能源消耗
肥胖管理
疾病
减肥
生物信息学
慢性病
体重管理
慢性病
环境卫生
老年学
体重
食物摄入量
病理生理学
卫生专业人员
能量代谢
代谢性疾病
药物开发
风险分析(工程)
梅德林
脂肪堆积
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2026-11-05
卷期号:394 (6824): 626-632
标识
DOI:10.1126/science.aej1120
摘要
Obesity is now widely recognized as a chronic progressive condition. The altered biological mechanisms that cause obesity frequently require long-term treatment, including pharmacotherapies or bariatric surgery. In recent decades, the pathophysiology of obesity has been understood to an extent that obesity management medication (OMM) discovery could be rationally pursued. Advances in defining the regulation of food intake and energy expenditure by molecular communication from peripheral organs to the brain led to the development of OMMs that appear capable of safely achieving scalable and sustained body weight loss. However, side effects, heterogeneous treatment responses, long-term metabolic adaptations, adherence, and other factors may limit the use of existing OMMs and justify the development of additional medications to improve the health of people living with obesity.
科研通智能强力驱动
Strongly Powered by AbleSci AI